 |
200 Diseases |  |
191 Trials |
|
191 Trials |  |
19915 News |  |
| «12...192193194195196197198199200201202203204 |
- Humira (adalimumab) / Eisai, AbbVie
Trial completion: Predictors of the Response to Adalimumab in Rheumatoid Arthritis (clinicaltrials.gov) - Feb 7, 2012
P4, N=200, Completed, Sponsor: University Hospital, Rouen
Recruiting --> Completed
- Humira (adalimumab) / AbbVie
Trial completion: A Study of Adalimumab to Treat Sarcoidosis of the Skin (clinicaltrials.gov) - Feb 4, 2012
P2, N=16, Completed, Sponsor: Pariser, Robert J., M.D.
Recruiting --> Completed Recruiting --> Completed
- |||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Combination therapy: Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis (clinicaltrials.gov) - Feb 1, 2012
P2, N=54, Completed, Sponsor: Biogen Idec
Recruiting --> Completed Active, not recruiting --> Completed
- Humira (adalimumab) / AbbVie
Enrollment open: CASTIP: The Influence of Adalimumab on Cardiovascular and Metabolic Risk in Psoriasis (clinicaltrials.gov) - Jan 18, 2012
P4, N=66, Recruiting, Sponsor: Medical University of Vienna
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), Humira (adalimumab) / Eisai, AbbVie
New P4 trial, Pneumococcal vaccines: Efficacy Study of Pneumococcal Vaccination in Crohn's Disease (clinicaltrials.gov) - Jan 5, 2012
P4, N=172, Recruiting, Sponsor: Kyunghee University Medical Center
- ||||| Humira (adalimumab) / Eisai, AbbVie
Enrollment closed: Study of Adalimumab in Participants With Peripheral Spondyloarthritis (SpA) (clinicaltrials.gov) - Jan 3, 2012
P3, N=154, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||||| Humira (adalimumab) / Eisai, AbbVie
New P2 trial: A Crossover Study of the Safety and Tolerability of Two Formulations of Adalimumab (clinicaltrials.gov) - Dec 28, 2011
P2, N=61, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
- ||| Humira (adalimumab) / Eisai, AbbVie
Enrollment open: Effectiveness of Adalimumab in Moderate to Severe Plaque Psoriasis Patients With Distinct Co-morbidities (clinicaltrials.gov) - Dec 27, 2011
P=N/A, N=266, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Cimzia (certolizumab pegol) / Astellas, UCB
New P4 trial: Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate (clinicaltrials.gov) - Dec 26, 2011
P4, N=892, Active, not recruiting, Sponsor: UCB Pharma SA
- ||| Humira (adalimumab) / AbbVie
New P3 trial: Efficacy of Humira in Behcet Patients With Arthritis (clinicaltrials.gov) - Dec 20, 2011
P3, N=15, Recruiting, Sponsor: Rambam Health Care Campus
- ||| Humira (adalimumab) / Eisai, AbbVie
Clinical data, Trial completion, Compliance: EviraEAST: EValuation of HumIRA® in Patients With Active Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis in EASTern European Countries (clinicaltrials.gov) - Dec 19, 2011
P=N/A, N=809, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- || Humira (adalimumab) / AbbVie
New P3 trial: Efficacy and Safety of Adalimumab for the Induction of Clinical Response in Ulcerative Colitis (clinicaltrials.gov) - Dec 15, 2011
P3, N=200, Recruiting, Sponsor: Clalit Health Services
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion, Compliance: Study to Characterize Demographics, Compliance, Tolerability and Safety in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Prescribed Adalimumab (Humira®) as Part of Routine Clinical Care (clinicaltrials.gov) - Dec 12, 2011
P=N/A, N=252, Completed, Sponsor: Abbott
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| Tremfya (guselkumab) / J&J
New P2 trial: X-PLORE: A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis (clinicaltrials.gov) - Nov 29, 2011
P2, N=293, Active, not recruiting, Sponsor: Janssen Inc.
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
New P3 trial: PIONEER II: Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa (clinicaltrials.gov) - Nov 7, 2011
P3, N=300, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
New P3 trial: PIONEER I: Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa (clinicaltrials.gov) - Nov 7, 2011
P3, N=309, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
- || Humira (adalimumab) / Eisai, AbbVie
Trial completion, PK/PD data: Safety, Efficacy, and Pharmacokinetics of Adalimumab in Japanese Children With Juvenile Rheumatoid Arthritis (clinicaltrials.gov) - Oct 24, 2011
P3, N=25, Completed, Sponsor: Abbott
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
New P4 trial: A Randomised, Pragmatic, Open-label study of Adalimumab versus Etanercept for Rheumatoid Arthritis. (EUDRACT) - Oct 17, 2011
P4, N=124, Ongoing, Sponsor: University Hospital Birmingham NHS Foundation Trust
- ||| Humira (adalimumab) / Eisai, AbbVie
Enrollment open: PASSION: Observational Study to Explore the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP) (clinicaltrials.gov) - Sep 26, 2011
P=N/A, N=1500, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
Clinical: Study of Antibodies to Anti-TNF Agents in Juvenile Idiopathic Arthritis (clinicaltrials.gov) - Sep 12, 2011
P=N/A, N=100, Not yet recruiting, Sponsor: Blood Transfusion Centre of Slovenia
- Humira (adalimumab) / Eisai, AbbVie
Trial withdrawal: Study to Determine the Efficacy of Adalimumab in the Treatment of Cutaneous Sarcoidosis (clinicaltrials.gov) - Sep 7, 2011
P2, N=5, Withdrawn, Sponsor: Wake Forest School of Medicine
Not yet recruiting --> Recruiting Not yet recruiting --> Withdrawn
- ||| Humira (adalimumab) / Eisai, AbbVie
Enrollment open, P4 data: Complete-PS: Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Psoriasis (clinicaltrials.gov) - Aug 31, 2011
P=N/A, N=660, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Not yet recruiting --> Withdrawn Not yet recruiting --> Recruiting
- | Humira (adalimumab) / AbbVie
Trial completion: Efficacy and Safety of Adalimumab in Patients With Psoriasis and Obstructive Sleep Apnea (clinicaltrials.gov) - Aug 31, 2011
P4, N=20, Completed, Sponsor: Innovaderm Research Inc.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Humira (adalimumab) / Eisai, AbbVie
Trial completion: Primary UVB-311nm and Adalimumab in Psoriasis Patients (clinicaltrials.gov) - Aug 8, 2011
P=N/A, N=4, Completed, Sponsor: Medical University of Graz
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Humira (adalimumab) / Eisai, AbbVie
Enrollment open, P4 data: Complete-AS: Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis (clinicaltrials.gov) - Aug 7, 2011
P=N/A, N=1120, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||||||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: A Study of Adalimumab in Japanese Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Aug 7, 2011
P3, N=334, Completed, Sponsor: Abbott
Not yet recruiting --> Recruiting Active, not recruiting --> Completed